Free Trial

3 reasons 2024 Moderna shareholders may party like it's 2021

Key Points

  • Moderna has a dominant grasp on the Covid vaccine market — and a significant revenue contributor for years to come.
  • Moderna’s second commercialized product is expected to be the RSV vaccine MRNA-1345, a catalyst Moderna shareholders have long awaited.
  • Oppenheimer analyst Hartaj Singh kicked off the new year by upgrading MRNA to a Buy.
  • 5 stocks we like better than Moderna.

unlock icon  Upgrade Now

This premium article is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

→ Has Trump Finally Gone Too Far? (From Insiders Exposed) (Ad)

Should you invest $1,000 in Moderna right now?

Before you consider Moderna, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.

While Moderna currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Moderna (MRNA)
4.2818 of 5 stars
$39.39-0.4%N/A-6.77Hold$79.50
Merck & Co., Inc. (MRK)
4.9881 of 5 stars
$98.05-1.5%3.14%20.56Moderate Buy$127.13
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Alphabet Gaining Momentum: Can It Reach $200 by December?

Alphabet Gaining Momentum: Can It Reach $200 by December?

Alphabet (GOOGL) is in the midst of a year-end rally, climbing 10% since September, and some analysts predict it could gain another 30% by Christmas!

Recent Videos

From Landfills to Profits: Opal Fuels CEO Shares How the Company Turns Trash into Cash
The Real Reason Tesla Stock Is Soaring – and Why Tech Expert Says It Won’t Stop
Best ETFs for 2025: Growth, Stability, and AI-Driven Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines